AstraZeneca plc (ADR) Just Recorded A Sigfniciant Bearish Options Activity

 AstraZeneca plc (ADR) Just Recorded A Sigfniciant Bearish Options Activity

In today’s session AstraZeneca plc (ADR) (AZN) recorded an unusually high (5,057) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious AZN decrease. With 5,057 contracts traded and 89324 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: AZN161118P00027000 closed last at: $0.4 or 33.3% up. About 912,091 shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has declined 4.08% since April 12, 2016 and is downtrending. It has underperformed by 9.06% the S&P500.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 39.38% above today’s ($27.55) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, February 26 by Cantor Fitzgerald. The stock has “Buy” rating given by Jefferies on Monday, September 12. BNP Paribas downgraded the shares of AZN in a report on Wednesday, September 14 to “Neutral” rating. As per Friday, September 23, the company rating was initiated by Piperjaffray. The firm earned “Underperform” rating on Tuesday, October 20 by Credit Suisse. The company was upgraded on Tuesday, January 26 by Oddo & Cie. On Monday, November 2 the stock rating was downgraded by Nordea to “Hold”. The rating was upgraded by Swedbank to “Buy” on Friday, July 31. S&P Research upgraded the stock to “Buy” rating in Friday, July 31 report. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Overweight” rating given on Tuesday, December 1 by Morgan Stanley.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $68.38 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 28.29 P/E ratio. The Firm has its activities in over 100 countries.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment